Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI
Agreement provides Rakovina exclusive access to its optimized kt-5000 target profile and extends AI-powered lead optimization through year-end at no additional cost VANCOUVER, British Columbia, Oct. 14, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery,…
Read original article on Financial Post →Related news
-
'It's so strange, it's perfect': Angine de Poitrine's album illustrator on why we need their art right now
-
Who else besides Danielle Smith is saying 'yes to the nine' in Alberta's referendum?
-
Trial set to begin for former Calgary bar owner accused of sexually assaulting 5 women
-
Fact-checking the B.C. NDP's environmental record
- Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Board of Directors
- Pan Global Expands Near-Surface High-Grade Gold Discovery at Cármenes Project, Spain: Drillholes Return 7.29g/t Au Over 9 Meters and 1.53g/t Au Over 38 Meters
-
Watch the B.C. election provincial leaders’ debate live
- TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity